J
Jan J. Jobsen
Researcher at Medisch Spectrum Twente
Publications - 94
Citations - 7829
Jan J. Jobsen is an academic researcher from Medisch Spectrum Twente. The author has contributed to research in topics: Breast cancer & Endometrial cancer. The author has an hindex of 33, co-authored 80 publications receiving 6395 citations.
Papers
More filters
Journal ArticleDOI
Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial
Carien L. Creutzberg,Wim L.J. van Putten,Peter C.M. Koper,M.L.M. Lybeert,Jan J. Jobsen,C.C. Wárlám-Rodenhuis,Karin A.J. De Winter,Ludy C.H.W. Lutgens,Alfons C.M. van den Bergh,Elzbieta van de Steen-Banasik,H Beerman,Mat van Lent +11 more
TL;DR: In this article, the authors did a multicentre prospective randomised trial to find whether postoperative pelvic radiotherapy improves locoregional control and survival for patients with stage-1 endometrial carcinoma.
Journal ArticleDOI
Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial
Remi A. Nout,Vthbm Smit,Hein Putter,I.M. Jürgenliemk-Schulz,Jan J. Jobsen,L.C.H.W. Lutgens,E. Van der Steen-Banasik,Jwm Mens,Annerie Slot,M. C. Stenfert Kroese,Bnfm van Bunningen,AC Ansink,Wlj van Putten,Carien L. Creutzberg +13 more
TL;DR: VBT is effective in ensuring vaginal control, with fewer gastrointestinal toxic effects than with EBRT, and should be the adjuvant treatment of choice for patients with endometrial carcinoma of high-intermediate risk.
Journal ArticleDOI
Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—Combined Analysis of the PORTEC Cohorts
Ellen Stelloo,Remi A. Nout,Elisabeth M. Osse,Ina J. Jürgenliemk-Schulz,Jan J. Jobsen,Ludy C.H.W. Lutgens,Elzbieta van der Steen-Banasik,Hans W. Nijman,Hein Putter,Tjalling Bosse,Carien L. Creutzberg,Vincent T.H.B.M. Smit +11 more
TL;DR: Assessment of this integrated risk profile is feasible in daily practice, and holds promise to reduce both overtreatment and undertreatment, in patients with early-stage endometrial carcinoma.
Journal ArticleDOI
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial
Stephanie M. de Boer,Melanie E Powell,Linda Mileshkin,Dionyssios Katsaros,Paul Bessette,Christine Haie-Meder,Petronella B. Ottevanger,Jonathan A. Ledermann,Pearly Khaw,Alessandro Colombo,Anthony Fyles,Marie Helene Baron,Ina M. Jürgenliemk-Schulz,Henry C Kitchener,Hans W. Nijman,G. Wilson,Susan Brooks,Silvestro Carinelli,Diane Provencher,Chantal Hanzen,Ludy C.H.W. Lutgens,Vincent T.H.B.M. Smit,Naveena Singh,V. Do,Romerai D'Amico,Remi A. Nout,Amanda Feeney,Karen W Verhoeven-Adema,Hein Putter,Carien L. Creutzberg,Mary McCormack,Karen Whitmarsh,Rozenn Allerton,Deborah Gregory,P. Symonds,Peter Hoskin,Madhavi Adusumalli,Anjana Anand,Robert Wade,Alexandra J. Stewart,Wendy Taylor,Roy F.P.M. Kruitwagen,Harry Hollema,Elizabeth Pras,An Snyers,Lukas J.A. Stalpers,Jan J. Jobsen,Annerie Slot,Jan Willem M. Mens,Tanja C. Stam,Baukelien Van Triest,Elzbieta M. Van der Steen Banasik,Karin A.J. De Winter,Michael A. Quinn,Ilka Kolodziej,Jan Pyman,Carol Johnson,Anne Capp,Roldano Fossati,Sergio Gribaudo,Andrea Lissoni,Annamaria Ferrero,Grazia Artioli,Cathy Davidson,C. Meg McLachlin,Prafull Ghatage,Paula V.C. Rittenberg,Luis Souhami,Gillian Thomas,Pierre Duvillard,Dominique Berton-Rigaud,Nicole Tubiana-Mathieu +71 more
TL;DR: Adjuvant chemotherapy given during and after radiotherapy for high-risk endometrial cancer did not improve 5-year overall survival, although it did increase failure-free survival.
Journal ArticleDOI
Survival after relapse in patients with endometrial cancer: results from a randomized trial.
Carien L. Creutzberg,Wim L.J. van Putten,Peter C.M. Koper,M.L.M. Lybeert,Jan J. Jobsen,C.C. Wárlám-Rodenhuis,Karin A.J. De Winter,Ludy C.H.W. Lutgens,Alfons C.M. van den Bergh,Elzbieta van der Steen-Banasik,H Beerman,Mat van Lent +11 more
TL;DR: As pelvic RT was shown to improve locoregional control significantly, but without a survival benefit, its use should be limited to those patients at sufficiently high risk for recurrence in order to maximize local control and relapse-free survival.